C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) A61K 38/00 (2006.01) A61K 45/00 (2006.01) A61P 1/10 (2006.01) A61P 1/14 (2006.01) A61P 43/00 (2006.01) C12Q 1/02 (2006.01) C07K 14/47 (2006.01) C12N 1/15 (2006.01) C12N 1/19 (2006.01) C12N 1/21 (2006.01) C12N 5/10 (2006.01) C12N 15/09 (2006.01) G01N 33/566 (2006.01)
Patent
CA 2638943
Disclosed is an agent capable of ameliorating the intestinal tract dysfunction through a novel action mechanism. Also disclosed is a method for the evaluation of a compound, including the screening of the agent. A disease accompanied by intestinal tract dysfunction can be ameliorated or treated by using an NPY Y4 agonist as a therapeutic agent. A compound capable of ameliorating or treating a disease accompanied by intestinal tract dysfunction can be evaluated or screened by evaluating a compound targeting to an NPY Y4 receptor.
La présente invention concerne un agent capable d'améliorer le dysfonctionnement du tractus intestinal par le biais d'un nouveau mécanisme d'action. La présente invention concerne un procédé d'évaluation d'un composé, y compris le criblage de l'agent. Une maladie associée à un dysfonctionnement du tractus intestinal peut être atténuée ou traitée par l'utilisation d'un agoniste NPY Y4 en tant qu'agent thérapeutique. Cette invention concerne un composé capable d'atténuer ou de traiter une maladie associée à un dysfonctionnement du tractus intestinal, en évaluant un composé ciblant un récepteur NPY Y4.
Hirose Hiroyasu
Kanatani Akio
Kanno Tetsuya
Moriya Ryuichi
Suzuki Jun
Banyu Pharmaceutical Co. Ltd.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Npy y4 agonist as therapeutic agent for disease accompanied... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Npy y4 agonist as therapeutic agent for disease accompanied..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Npy y4 agonist as therapeutic agent for disease accompanied... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1809001